Dogwood Therapeutics, Inc. DWTX
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
Dogwood Therapeutics, Inc. (DWTX) is a healthcare company listed in the US with a market value of about $42M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is value (2/5); the weakest is future growth (0/5).
Key numbers: a P/E of 0.1, a 5-year average ROIC of -90%.
About Dogwood Therapeutics
Dogwood Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2020. It was profitable in 0 of the last 6 years in our data. Its share count rose by 1024% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net income | -$34M | -$12M | -$5M | -$12M | -$16M | -$10M |
| Free cash flow | -$16M | -$9M | — | — | — | — |
| EPS (diluted) | $-7.13 | $-12.52 | $-7.05 | $-27.75 | $-48.00 | $-52.50 |
| Net margin | — | — | — | — | — | — |
| ROIC | -29.4% | — | -113.0% | -132.8% | -85.2% | -26.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Dogwood Therapeutics’s P/E ratio?
About 0.1, based on the last twelve months of diluted earnings per share.
Does Dogwood Therapeutics pay a dividend?
Not currently.
Is Dogwood Therapeutics a good stock to buy?
We do not give buy or sell advice. Dogwood Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.